WILL R VOELZKE
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology RICHMOND, VA NPI 1023205697
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology VA Janssen Biotech, Inc. All categories
General Payments — all program years on this page
$3,753.80
- Category: General Payments
- Program years: PY2018–2024
- Record count: 183
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,535.77 across 66 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,535.77 | 66 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $175.33 | 7 |
| PFIZER INC. | $161.09 | 8 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $129.82 | 6 |
| Acerta Pharma LLC | $116.16 | 4 |
| E.R. Squibb & Sons, L.L.C. | $94.53 | 5 |
| US Oncology Corporate, Inc. | $83.20 | 1 |
| Merck Sharp & Dohme Corporation | $70.00 | 3 |
| Ipsen Biopharmaceuticals, Inc | $50.46 | 2 |
| Regeneron Healthcare Solutions, Inc. | $48.22 | 2 |
| Genentech USA, Inc. | $48.19 | 2 |
| GlaxoSmithKline, LLC. | $46.50 | 2 |
| SOBI, INC | $41.62 | 2 |
| Lilly USA, LLC | $39.91 | 2 |
| EISAI INC. | $39.16 | 2 |
| Astellas Pharma US Inc | $38.42 | 2 |
| Acrotech Biopharma Inc. | $34.97 | 2 |
| ABBVIE INC. | $31.69 | 1 |
| Coherus Biosciences Inc. | $30.08 | 1 |
| GENZYME CORPORATION | $29.34 | 1 |
| TAIHO ONCOLOGY, INC. | $29.20 | 1 |
| Stemline Therapeutics Inc. | $26.13 | 1 |
| Novocure Inc. | $25.36 | 1 |
| PharmaEssentia USA Corporation | $23.04 | 1 |
| Legend Biotech USA Inc. | $22.47 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.63 | 1 |
| Daiichi Sankyo Inc. | $20.03 | 1 |
| Celgene Corporation | $17.67 | 1 |
| Sumitomo Pharma America, Inc. | $16.39 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $16.13 | 1 |
| Rigel Pharmaceuticals, Inc. | $9.03 | 1 |
By program year
Records — PY2024 (66)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.